**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Mazen A. Hanna, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA; HANNAM@ccf.org

**Main Body of the Abstract**
Background: Based on findings from the Phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis meglumine 80 mg and bioequivalent free acid 61 mg are approved disease-modifying treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). In a post hoc analysis of pooled doses (meglumine 80 and 20 mg), tafamidis was associated with significantly higher odds of improvement in six-minute walk test (6MWT) distance, Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score, Patient Global Assessment (PGA) of overall health, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration vs placebo after 30 months.
Methods: This analysis evaluated the proportion of ‘improvers’ among patients who took the approved dose of tafamidis meglumine (80 mg) in ATTR-ACT with and without imputation of missing values as worsened.
Results: After 12- and 30-months of treatment, higher proportions of patients taking tafamidis 80 mg (n=176 at baseline) than placebo (n=177) showed improvement in 6MWT distance, KCCQ-OS score, PGA of overall health, and NT-proBNP concentration (Figure). Odds ratios at 30 months, by both observed and imputed methodology, significantly favored tafamidis for improvement in all disease measures (Figure).
Conclusions: A higher likelihood of improvement in a range of disease measures was seen in patients who received tafamidis meglumine 80 mg vs placebo for 30 months in ATTR-ACT. These findings provide further evidence supporting the efficacy of the approved tafamidis dose in patients with ATTR-CM. NCT01994889



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Mazen A. Hanna, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA; HANNAM@ccf.org

**Main Body of the Abstract**
**Background:** Based on findings from the Phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis meglumine 80 mg and bioequivalent free acid 61 mg are approved disease-modifying treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). In a post hoc analysis of pooled doses (meglumine 80 and 20 mg), tafamidis was associated with significantly higher odds of improvement in six-minute walk test (6MWT) distance, Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score, Patient Global Assessment (PGA) of overall health, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration vs placebo after 30 months.
**Methods:** This analysis evaluated the proportion of ‘improvers’ among patients who took the approved dose of tafamidis meglumine (80 mg) in ATTR-ACT with and without imputation of missing values as worsened.
**Results:** After 12- and 30-months of treatment, higher proportions of patients taking tafamidis 80 mg (n=176 at baseline) than placebo (n=177) showed improvement in 6MWT distance, KCCQ-OS score, PGA of overall health, and NT-proBNP concentration (Figure). Odds ratios at 30 months, by both observed and imputed methodology, significantly favored tafamidis for improvement in all disease measures (Figure).
**Conclusions:** A higher likelihood of improvement in a range of disease measures was seen in patients who received tafamidis meglumine 80 mg vs placebo for 30 months in ATTR-ACT. These findings provide further evidence supporting the efficacy of the approved tafamidis dose in patients with ATTR-CM. NCT01994889



Tafamidis 80 mg is more likely to improve disease measures than placebo in patients with transthyretin amyloid cardiomyopathy PC90 (#2)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.